From left to right: Girts Cimermans, CEO of medmix, James Kirk, Site Lead in Flowery Branch; Jennifer Dean, Chief Financial Officer of medmix; Xavier Schops, General Counsel, Company Secretary, and Global Head of Legal, Compliance and Risk Management of medmix, and Levi Quinn, Chief Operating Officer of medmix.

A Swiss medical device company is set to invest at least $20 million to outfit a leased facility northeast of Atlanta with clean room space as it expands into the U.S. market.

Medmix recently took over the 300,000-square-foot space in Flowery Branch and is now building it out to support the full gamut of the company’s health care business.

Some 200 jobs will be created in Hall County as the site is constructed in phases over the next five to seven years, the company said in a news release. 

Medmix health care’s drug-delivery division will provide pen injectors and auto-injectors as well as pharmaceutical packaging services from the site. Its surgery unit will support sales of fluid handling devices, and the dental unit will bring manufacturing and customer service for fillings into the U.S. market. 

“The new site will allow us to reduce lead times, optimize supply chain and increase service levels for our health care customers in the U.S. It will also enable us to easily scale up to larger volumes, supporting our ambitious growth plans,” said Girts Cimermans, the Medmix CEO, in a news release. 

Dental makes up 70 percent of the revenues in the three-pronged health segment. Operating a global network, Medmix is also active in the industrial and beauty segments, making mascara brushes and lipgloss applicators along with mixing and dispensing systems for adhesives and sealants. 

The metro Atlanta move comes at a time of rapid growth and ambitious overseas expansion at the Baar, Switzerland-based spinoff from Sulzer Ltd. Medmix recently acquired a beauty company in China and a plastics business in Spain, while exiting Poland after the country shut down its factory after determining — wrongly, the company has appealed — that a sanctioned Russian oligarch had interests in the subsidiary. 

Revenues for the first half of 2022 stood at 250.6 million Swiss francs, about $272 million. Medmix is set to release full-year earnings on Feb. 27 and expects revenues of 460-470 million francs (about $500 million) even after an impairment charge of 30-40 million francs based on the Polish shutdown. 

As managing editor of Global Atlanta, Trevor has spent 15+ years reporting on Atlanta’s ties with the world. An avid traveler, he has undertaken trips to 30+ countries to uncover stories on the perils...

Join the Conversation

1 Comment